The following is a summary of remarks by Imunon's President and CEO Stacy Lindborg, PhD. on the second quarter 2025 financial results conference call, provided for Shareholders unable to join the call: Advancing the Pivotal Phase 3 OVATION 3 Trial for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer: The Company is well-positioned for efficient and timely execution of this pivotal Phase 3 study, and has enrolled and begun treating its first patient on the protocol, building on the robust Phase 2 OVATION ...

Core Viewpoint - IMUNON, Inc. is set to host a conference call on August 5, 2025, to discuss its Q2 2025 financial results and provide updates on its clinical development program, particularly focusing on the Phase 3 trial of its DNA-based immunotherapy, IMNN-001, for advanced ovarian cancer [1]. Company Overview - IMUNON is a clinical-stage biotechnology company that develops innovative treatments utilizing the body's natural mechanisms to generate effective responses against various diseases, differentiating itself from conventional therapies [4]. - The company is advancing its non-viral DNA technology through two main modalities: TheraPlas® for gene-based delivery of cytokines and PlaCCine® for gene delivery of viral antigens [4]. Clinical Development - The lead clinical program, IMNN-001, is a DNA-based immunotherapy targeting advanced ovarian cancer, which has completed multiple trials, including a Phase 2 trial (OVATION 2) [5]. - The first site for the Phase 3 pivotal study (OVATION 3) was initiated in Q2 2025, with IMNN-001 designed to instruct the body to produce cancer-fighting molecules at the tumor site [5]. - Additionally, the company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101) [5].

Core Insights - IMUNON, Inc. announced positive results from a Phase 1 clinical trial of its investigational DNA plasmid vaccine, IMNN-101, which demonstrated better durability of protection compared to mRNA vaccines after a single dose targeting the SARS-CoV-2 Omicron XBB1.5 variant [3][4] - The company is seeking strategic partnerships to advance its PlaCCine technology platform and fund its core pipeline with non-dilutive capital [1][4] Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing non-viral DNA-mediated immunotherapies and next-generation vaccines [1][8] - The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, which has completed multiple clinical trials [9] Clinical Trial Details - The Phase 1 trial enrolled 24 participants and evaluated three escalating doses of IMNN-101, with a focus on safety, tolerability, and immunogenicity [6] - Results indicated a median increase of up to 3-fold in serum neutralizing antibody titers at six months, with no serious adverse effects reported [3][6] Technology Advantages - The PlaCCine technology platform offers several competitive advantages, including better durability of protection, temperature stability, and ease of manufacturing compared to current mRNA vaccines [4][5] - IMNN-101 utilizes a proprietary DNA plasmid that regulates the expression of key pathogen antigens, providing flexibility in manufacturing and delivery [5]